Taysha Gene Therapies (TSHA) Other financing activities (2020 - 2026)

Taysha Gene Therapies has reported Other financing activities for 6 years, with the latest figure at $19000.0 in Q1 2026.

• Quarterly Other financing activities fell 74.67% year-over-year to $19000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 1045.65% YoY) and the FY2025 annual result came in at $1.6 million, up 1739.33% from the prior year.
• Other financing activities declined to $19000.0 in Q1 2026 per TSHA's latest filing, from $1.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $1.9 million in Q4 2025 and troughed at -$1.3 million in Q4 2022.
• A 5-year average of $51400.0 and a median of $19000.0 in 2026 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2025: Other financing activities plunged 345.59% in 2023, then surged 530.1% in 2025.
• Over 5 years, Other financing activities stood at -$1.3 million in 2022, then jumped by 124.79% to $321000.0 in 2023, then retreated by 6.85% to $299000.0 in 2024, then soared by 530.1% to $1.9 million in 2025, then tumbled by 98.99% to $19000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $19000.0, $1.9 million, and -$285000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.